>>> In addition to clinical trials, we have also provided ZEN-3694 for compassionate use to multiple patients with these diseases and are excited to soon announce results from these important studies.

 We are very pleased that NUT carcinoma patients receiving ZEN-3694 in clinical trial and compassionate use settings have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.

We are also excited about exploring the activity of ZEN-3694 in MPNST, a rare cancer with devastating impact on patients' lives."<<<<

Hahahahahahahahahahaha,,,he is still excited,,,possibly wearing a depend??,,,how the Calgary office could maintain their irrational excuberance for so many years is a clinical trial in and of itself!!,,, LMAO,,,best suggestion,,,,dont believe one word the CEO tells us about either of these companys or what his expectations are!!..He has damaged shareholder optimism to the point of poisoning investment groups and is responsible for the failures and the complacency of both!! He can fool the newbies,,but he aint fooling us lifers,,we know him and can read thru his rhetoric!!!,,,,,10 years and counting for ZENE with no value appreciation or market made available to shareholders!!!